The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
The drop in the SP is probably due to the herd running over to EUA...
The accounts are overdue and I guess they have spent all our money "The End".
I would hate to see the sp if it was bad news.
Further flow testing results will be provided to shareholders over the coming weeks including the analysis of downhole pressure measurement and fluid sampling as well as the results of any future clean up stimulation or testing programs.
corporate action open Offer details
Omega Diagnostics Group plc has announced its intention to raise cash by way of an open offer.
The Open Offer will be available to all Shareholders as at close of business on 19 June 2020. If you hold Shares at this time you will be entitled to purchase 1 new Share for every 20 Shares held, at a price of 40p per Share. Excess applications will also be available.
Entitlements to participate will be issued from Tuesday 23 June. You need to take no action at present. We will write to Qualifying Shareholders confirming full terms of the Open Offer shortly after 23 June 2020, at which point an online election facility will be enabled for qualifying shareholders to give an instruction. Our deadline for the Open Offer is expected to be noon on Friday 3 July 2020.
MM tree shake - Good morning America :)
MM could be dropping the price for a big fill order.
ODX will probably 10 bag IMHO
Robidicus, I think something is going on in the background. The UK app only shows UK downloads. I wonder if any of our US friends could shed alight on how many times the app has been downloaded.
I would assume Melodyvr are in charge of the app and the data that they release. I know apple doesn't release this info as standard. Maybe there is a reason they are keeping a lid on these figures.
https://www.wbur.org/artery/2020/05/04/coronavirus-pandemic-music-industry-concerts
VR will be the only way for people to enjoy shows for the foreseeable future.
https://www.bbc.co.uk/news/av/business-52639711/abba-s-bjrn-ulvaeus-fears-for-future-of-west-end-theatres
https://www.tpr.org/post/san-antonio-company-develops-new-test-lung-cancer
Commenting Allan Syms, Chairman of Bould, said: “I am pleased that we have identified an
exciting target in the biotechnology sector and are working towards completing the Proposed
Transaction and admitting the Bould shares to trading on a recognised stock exchange as soon
as possible.
“The Covid-19 pandemic is obviously a concern for all and whilst it is constraining certain
elements of the process to complete the Proposed Transaction and listing, we are still able to
make progress and are working hard to conclude matters. I look forward to providing further
updates in due course.”
For further information:
Bould Opportunities plc c/o IFC Advisory
Allan Syms, Chairman
IFC Advisory Limited (Financial PR & IR) +44(0)20 3934 6630
Tim Metcalfe bould@investor-focus.co.uk
Florence Chandler
8 April 2020
Bould Opportunities plc
("Bould Opportunities" or the "Company")
Corporate Update
Bould Opportunities is pleased to provide an update to shareholders concerning the current
status of the Company and its future plans.
As shareholders will note, the Company was formerly classified as an AIM Rule 15 cash shell
and as such was required to make an acquisition or acquisitions which constitutes a reverse
takeover under AIM Rule 14 ("Reverse Takeover") or be re-admitted to trading on AIM as an
investing company under the AIM Rules (which requires the raising of at least £6 million)
within a specified timescale. As neither a Reverse Takeover nor re-admission to trading on
AIM as an investing company under the AIM Rules was achieved within the required
timescale, the admission to trading of the Company’s shares on AIM was cancelled with effect
from 7.00 a.m. today.
For the avoidance of doubt, following the cancellation of the admission to trading on AIM of
the Company’s shares all shareholders remain as shareholders in the Company. The Directors
appreciate the concerns of shareholders in not being able to trade their shares and are
working hard to facilitate admission of the Company’s shares to trading on a recognised stock
exchange as soon as possible, alongside the completion of an appropriate acquisition.
To that end the Company, together with its various professional advisers, has been working
for some time to complete the acquisition of an identified target (the “Target”) in the
biotechnology sector (the “Proposed Transaction”). The Proposed Transaction , if completed,
would comprise the acquisition of a company with a technology and patent portfolio focussed
on the early detection of a specific cancer. This is an exciting opportunity to provide a new
diagnostic test for cancer that addresses unmet clinical need for early detection. Early
detection is proven to increase five year survival rates. Whilst there can be no guarantee that
the Proposed Transaction will complete, the Directors believe that it will provide an
opportunity to develop an exciting company in the biotechnology sector, providing value for
Bould shareholders. For confidentiality reasons no further information on the Target can be
disclosed at the present time.
Despite the constraints imposed by the Covid-19 pandemic and the uncertainties surrounding
timetables that inevitably have arisen, the Directors and the Company’s professional advisers
are working hard to progress the Proposed Transaction to completion, together with the
admission of the Company’s shares to trading on a recognised stock exchange as soon as
possible. Further updates will be provided through the Bould Opportunities website and
announced as appropriate.
Commenting Allan Syms, Chairman of Bould, said: “I am pleased that we have identified an
exciting target in the biotechnology sector and are working towards completing the Proposed
Transaction and admitting the Bou
One would have expected an RNS from the BOD at this late stage.
As far as I am aware they are setting up a couple of VR studios for the artists to attend and record. They will also be required to address legal and health & Safety for said studios. Then there is the issue with Artists actually wanting to leave their homes to do said gigs. Not really essential work is it?